Exoerythrocytic malaria vaccine development: Understanding host-parasite immunobiology underscores strategic success

Expert Review of Vaccines

Volumn 1, Issue 3, 2002, Pages 317-340

  Taylor Robinson, Andrew W ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Antigen; Immunity; Liver stage; Malaria; Plasmodium; Sporozoite; Vaccine

Indexed keywords

CIRCUMSPOROZOITE PROTEIN 2 VACCINE; CIRCUMSPROZOITE PROTEIN VACCINE; EPITOPE; GLUCOSE REGULATED PROTEIN 70 VACCINE; GLUTAMATE RICH PROTEIN VACCINE; HEAT SHOCK PROTEIN 70 VACCINE; LIVER STAGE ANTIGEN 1 VACCINE; LIVER STAGE ANTIGEN 2 VACCINE; LIVER STAGE ANTIGEN 3 VACCINE; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 1 VACCINE; PARASITE ANTIGEN; PLASMODIUM FALCIPARUM EXPORTED PROTEIN 1 VACCINE; PLASMODIUM YOELII HEPATIC AND ERYTHROCYTIC STAGE PROTEIN VACCINE; SPOROZOITE AND LIVER STAGE ANTIGEN; SPOROZOITE THREONINE AND ASPARAGINE RICH PROTEIN VACCINE; THROMBOSPONDIN RELATED ADHESION PROTEIN; TOMATINE; UNCLASSIFIED DRUG;

BLOOD; COST EFFECTIVENESS ANALYSIS; ERYTHROCYTE; EVALUATION; HOST PARASITE INTERACTION; IMMUNE RESPONSE; IMMUNOBIOLOGY; INFECTION PREVENTION; LIVER CELL; MALARIA; MOLECULAR BIOLOGY; MOSQUITO; NONHUMAN; PARASITE; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; REVIEW; SCORING SYSTEM; SPOROZOITE;

ANIMALS; ANTIGENS, PROTOZOAN; BETA 2-MICROGLOBULIN; CD8-POSITIVE T-LYMPHOCYTES; ERYTHROCYTES; HOST-PARASITE RELATIONS; HUMANS; LIVER; MALARIA; MALARIA VACCINES; PLASMODIUM; T-LYMPHOCYTES, REGULATORY;

EID: 0037654956     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.1.3.317     Document Type: Review

References (179)

1. Warrell DA. Clinical features of malaria. In: Bruce-Chwatt's Essential Malariology, 3rd edn. Gilles HM, Warrell DA (Eds), Edward Arnold, London, UK, 35-49 (1993).
2. Taylor-Robinson AW. Vaccination against malaria: targets, strategies and potentiation of immunity to blood stage parasites. Front. Biosci. 5, 16-29 (2000).
3. Trigg PI, Kondrachine AV. The current global malaria situation. In: Malaria: Parasite Biology, Pathogenesis and Protection. Sherman IW (Ed.), ASM Press, Washington DC, USA, 11-22 (1998).
4. Ridley RG. Medical need, scientific opportunity and the drive for antimalarial drugs. Nature 415, 686-693 (2002). Excellent consideration of the need for novel antimalarial strategies and the public-private partnerships that need to be forged in order to build on scientific opportunities.
5. Taylor-Robinson AW. Immunoregulation of malarial infection: balancing the vices and virtues. Int. J. Parasitol. 28, 135-148 (1998).
6. Taylor-Robinson AW, Smith EC. A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection. Immunol. Rev. 171, 105-123 (1999).
7. Marsh K. Immunology of human malaria. In: Bruce-Chwatt's Essential Malarioloy, 3rd edn. Gilles HM, Warrell DA (Eds), Edward Arnold, London, UK, 60-77 (1993).
8. Miller L, Hoffman S. Research towards vaccines against malaria. Nature Med. 4, 520-524 (1998).
9. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a Th2 phenomenon? Immunol. Today 14, 353-356 (1993).
10. Hoffman SL, Franke E, Hollingdale MR, Druilhe P. Attacking the infected hepatocyte. In: Malaria Vaccine Development. Hoffman SL (Ed.), ASM Press, Washington DC, USA, 35-75 (1996).
11. Hollingdale MR, McCormick CJ, Heal KG, Taylor-Robinson AW, Boykins R, Kazura JW. Biology of malarial liver stages: implications for vaccine design. Ann. Trop. Med. Parasitol. 92, 411-417 (1998). Thorough overview of current knowledge of the molecular events controlling sporozoite invasion and exoerythrocytic stage development.
12. Taylor-Robinson AW. Immunity to liver stage malaria: considerations for vaccine design. Immunol. Res. 27, 13-29 (2002). Useful summary of recent research on immunity to the intrahepatic malaria parasite, especially the role of LSA-1 as a vaccine candidate molecule.
13. Clyde DF, Most H, McCarthy VC, Vanderberg JP. Immunization of man against sporozite-induced falciparum malaria. Am. J. Med Sci. 266, 169-177 (1973).
14. Hoffman SL, Goh LM, Luke TC et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J. Infect. Dis. 185, 1155-1164 (2002).
15. Nussenzweig RS, Vanderberg J, Most H, Orton C. Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. Nature 216, 160-162 (1967).
16. Matzinger P. Tolerance, danger and the extended family. Annu. Rev. Immunol. 12, 991-1045 (1994).
17. Rajan TV. Why does Plasmodium have a pre-erythrocytic cycle? Parasitol. Today 13, 284-286 (1997).
18. Krzych U, Guebre-Xabier M, Schwenk R. Malaria and the liver: tolerance and immunity to attenuated plasmodia sporozoites. In: T-lymphocytes in the Liver: Immunobiology, Pathology and Host Defense. Crispe IN (Ed.), Wiley-Liss, New York, NY, USA, 163-195 (1999). Considers the evidence for and against the liver as an immunologically privileged site for Plasmodium survival.
19. Hill AVS, Elvin J, Willis AC et al. Molecular analysis of the association of HLA-B53 and resistance to severe malaria. Nature 360, 434-439 (1992). Reveals the association between the human leukocyte antigen HLA-B53 that is common in West Africans and resistance to severe P. falcifarum malaria.
20. + T- cell-dependent protective immunity to an exoerythrocytic antigen of P. falciparum.
21. Crispe IN, Mehal WZ. Strange brew: T-cells in the liver. Immunol. Today 17, 522-525 (1996).
22. Silvie O, Semblat JP, Franetich JF, Hannoun L, Eling W, Mazier D. Effects of irradiation on Plasmodium falciparum sporozoite hepatic development: implications for the design of pre-erythrocytic malaria vaccines. Parasite Immunol. 24, 221-223 (2002).
23. Hollingdale MR, Leef JL, McCullough M, Beaudoin RL. In vitro culture of the exoerythrocytic stage of Plasmodium berghei from sporozoites. Science 213, 1021-1022 (1981).
24. Enserink M, Pennisi E. Researchers crack malaria genome. Science 295, 1207 (2002).
25. Rosenberg R, Wirtz RA, Schneider I, Burge R. An estimation of the number of sporozoites ejected by a feeding mosquito. Tans. R. Soc. Trop. Med. Hyg. 84, 209-212 (1990).
26. Ponnudurai T, Lensen AHW, Van Gemert GJ, Bolmer MG, Meuwissen JH. Feeding behaviour and sporozoite ejection by infected Anopheles stephensi. Trans. R. Soc. Trop. Med. Hyg. 85, 1504-1513 (1991).
27. Frevert U, Sinnis P, Cerami C, Shreffler W, Takacs B, Nussenzweig V. Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J. Exp. Med. 177, 1287-1298 (1993).
28. Müller HM, Reckmann I, Hollingdale MR, Bujard H, Robson KJ, Crisanti A. Thrombospondin-related anonymous protein of Plasdmodium falciparum binds specifically to sulfated glycoconjugates and to HepG2 hepatoma cells, suggesting a role for this molecule in sporozoite invasion of hepatocytes. EMBO J. 12, 2881-2889 (1993).
29. Hollingdale MR, Sinden RE, van Pelt J. Sporozoite invasion. Nature 362, 26 (1993).
30. Meis JFGM, Verhave JP, Ponnudurai T et al. Fine structure of the liver forms of the malaria parasite Plasmodium falciparum in human hepatocytes in vitro. Cell Tissue Res. 244, 345-350 (1985).
31. Aikawa M, Schwartz AL, Uni S, Nussenzweig RS, Hollingdale MR. Ultrastructure of in vitro cultured exoerythrocytic stage of Plasmodium berghei in a hepatoma cell line. Am. J. Trop. Med. Hyg. 33, 792-799 (1984).
32. Atkinson CT, Aley SB, Hollingdale MR, Aikawa M. Expression of Plasmodium berghei circumsporozoite protein on the surface of exoerythrocytic schizonts and merozoites. Am. J. Trop. Med. Hyg. 41, 9-17 (1989).
33. Renia L, Mattei D, Gonna J et al. A malaria-heat-shock-like determinant expressed on the infected hepatocyte surface is a target of antibody-dependent cell-mediated cytotoxic mechanisms by nonparenchymal liver cells. Eur. J. Immunol. 20, 1445-1449 (1990).
34. Krotoski WA, Garnham PCC, Cogswell FB et al. Observations on early and late post-sporozoite tissue stages in primate malaria. IV. Pre-erythrocytic schizonts and/or hypnozoites of Chesson and North Korean strains of Plasmodium vivax in the chimpanzee. Am. J. Trop. Med. Hyg. 35, 263-274 (1986).
35. Sigler CL, Leland P, Hollingdale MR. In vitro infectivity of irradiated P. berghei sporozoites to cultured hepatoma cells. Am. J. Trop. Med. Hyg. 33, 544-547 (1984).
36. Zhu J, Waters AP, Appiah A, McCutchan TF, Lal AA, Hollingdale MR. Stage-specific ribosomal RNA expression switched during sporozoite invasion of hepatocytes. J. Biol. Chem. 21, 12740-12744 (1990).
37. Scheller LF, Azad AF. Maintenance of protective immunity against malaria by persistent hepatic parasites derived from irradiated sporozoites. Proc. Natl Acad. Sci. USA 92, 4066-4068 (1995).
38. Guérin-Marchand C, Druilhe P, Galey B et al. A liver stage-specific antigen of Plasmodium falciparum characterized by gene cloning. Nature 329, 164-167 (1987).
39. Zhu J, Hollingdale MR. Structure of Plasmodium falciparum liver stage antigen-1. Mol. Biochem. Parasitol. 48, 223-226 (1991).
40. Fidock DA, Gras Masse H, Lepers JP et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T-cell determinants. J. Immunol. 153, 190-204 (1994).
41. Hollingdale MR, Aikawa M, Atkinson CT et al. Non-CS pre-erythrocytic protective antigens. Immunol. Lett. 25, 71-76 (1990).
42. Terzakis JA, Vanderberg JP, Foley D, Shustak S. Exoerythrocytic merozoites of Plasmodium berghei in rat hepatic Kupffer cells. J. Protozool. 26, 385-389 (1979).
43. Atkinson CT, Hollingdale MR, Aikawa M. Localization of a 230 kDa parasitophorous vacuole membrane antigen of Plasmodium berghei exoerythrocytic schizonts (LSA-2) by immunoelectron and confocal laser scanning microscopy. Am. J. Trop. Med. Hyg. 46, 533-537 (1992).
44. Joshi SK, Bharadwaj A, Chatterjee S, Chauchan VS. Analysis of immune responses against T- and B-cell epitopes from Plasmodium falciparum liver-stage antigen 1 in rodent malaria models and malaria-exposed human subjects in India. Infect. Immun. 68, 141-150 (2000).
45. Daubersies P, Thomas AW, Millet P et al. Protection against Plasmodium falciparum malaria in chimpanzees by immunization with the conserved pre-erythrocytic liverstage antigen 3. Nat. Med. 6, 1258-1263 (2000). In chimpanzees, which share a susceptability to P. falciparum liver-stage infection with humans, immunization with LSA-3 induced protection against sporozite challenge.
46. Bottius E, Mohamed L, Brahimi K et al. A novel Plasmodium falciparum sporozoite and liver stage antigen (SALSA) defines major B, T-helper and CTL epitopes. J. Immunol. 156, 2874-2884 (1996).
47. Meis JFGM, Yap PHK, Hollingdale MR, Verhave JP. Cellular response against exoerythrocytic from of Plasmodium berghei in rats. Am. J. Trop. Med. Hyg. 37, 506-510 (1987).
48. Charoenvit Y, Mellouk S, Sedegah M et al. Plasmodium yoelii: 17-kDa hepatic and erythrocytic stage protein is the target of an inhibitory monoclonal antibody. Exp. Parasitol. 80, 419-429 (1995).
49. Hope IA, Mackay M, Hyde JE, Goman M, Scaife J. The gene for an exported antigen of the malaria parasite Plasmodium falciparum cloned and expressed in Escherichia coli. Nucleic Acids Res. 13, 369-379 (1985).
50. Hogh B, Thompson R, Zakiuddin IS, Boudin C, Borre M. Glutamate-rich Plasmodium falciparum antigen (GLURP). Parassitologia 35(suppl.), 47-50 (1993).
51. Sina BJ, do Rosario VE, Woollett G, Hollingdale MR. P. berghei sporozoite immunization protects against P. berghei sporozoite infection. Exp. Parasitol. 77, 129-135 (1993).
52. Sina BJ, Wright C, Ballou WR, Hollingdale MR. A protective monoclonal antibody with dual specificity for Plasmodium falciparum and P. berghei circumsporozoite proteins. Exp. Parasitol. 74, 431-440 (1992).
53. Kumar N, Nagasawa H, Sacci JB et al. Expression of heat shock proteins (members of the hsp70 family) in the hepatic stages of Plasmodium falciparum and P. berghei. Parasitol. Res. 79, 109-113 (1993).
54. Szarfman A, Lyon JA, Walliker D et al. Mature liver stages of cloned Plasmodium falciparum share epitopes with proteins from sporozoites and asexual blood stages. Parasite Immunol. 10, 339-351 (1988).
55. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
56. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol. Today 17, 138-146 (1996).
57. Rabin EM, Mond JJ, Ohara J, Paul WE. Interferon-γ inhibits the action of B-cell stimulatory factor-1 on resting B-cells. J. Immunol. 137, 1573-1576 (1986).
58. Moore KW, O'Garra A, De Waal Malefyt R, Vieira P, Mosmann TR. Interleukin-10. Annu. Rev. Immunol. 11, 165-190 (1993).
59. Gajewski TF, Fitch FW. Antiproliferative effect of IFN-γ in immune regulation. IFN-γ inhibits the proliferation of Th2 but not Th1 murine helper T-lymphocyte clones. J. Immunol. 140, 4245-4252 (1988).
60. Allen JE, Maizels RM. Th1-Th2: reliable paradigm or dangerous dogma? Immunol. Today 18, 387-392 (1997).
61. Trinchieri G, Scott P. Interleukin-12: a pro-inflammatory cytokine with immunoregulatory functions. Res. Immunol. 146, 423-431 (1995).
62. Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by interleukin-12. Cell. Immunol. 143, 127-142 (1992).
63. + T-cells through IL-12 produced by Listeria-induced macrophages. Science 260, 547-549 (1993).
64. Sedegah M, Finkelman F, Hoffman SL. Interleukin-12 induction of interferon gamma-dependent protection against malaria. Proc. Natl Acad. Sci. USA 91, 10700-10702 (1994). Indicates that IL-12 stimulates non-B, non-T-cells to produce IFN-γ that kills intrahepatic parasites by stimulating NO production.
65. Good MF, Doolan DL. Immune effector mechanisms in malaria. Curr. Opin. Immunol. 11, 412-419 (1999).
66. Doolan DL, Hoffman SL. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453-1462 (2000).
67. Hollingdale MR, Nardin EH, Tharavanij S, Schwartz AL, Nussenzweig RS. Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J. Immunol. 132, 909-913 (1984).
68. Yoshida N, Nussenzweig RS, Potocnjak P, Nussenzweig V, Aikawa M. Hybridoma produces antibodies directed against the sporozoite stage of malaria parasite. Science 207, 71-73 (1980).
69. Krzych U, Lyon J, Jareed T et al. T-lymphocytes from volunteers immunized with irradiated Plasmodium falciparum sporozoites recognize liver and blood stage antigens. J. Immunol. 155, 4072-4077 (1995).
70. Good MF, Pombo D, Quakyi I et al. Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc. Natl Acad. Sci. USA 85, 1199-1203 (1987).
71. Fidock DA, Gras-Masse H, Lepers JP et al. Plasmodium falciparum liver stage antigen-1 is well conserved and contains potent B and T-cell determinants. J. Immunol. 153, 190-204 (1994).
72. Hoffman SL, Isenbarger D, Long G et al. Sporozoite vaccine induces genetically restricted T-cell elimination of malaria from hepatocytes. Science 244, 1078-1081 (1989).
73. + T-cells and antibodies required for immunity to malaria sporozoites. Nature 330, 664-666 (1987).
74. + T-cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl. Acad. Sci. USA 85, 573-576 (1988).
75. Weiss WR, Berzofsky JA, Houghten RA, Sedegah M, Hollingdale MR, Hoffman SL. A T-cell done directed at the circurmsporozoite protein which protects mice against both Plasmodium yoelii and P. berghei. J. Immunol. 149, 2103-2109 (1992).
76. Ferreira A, Schofield L, Enea V et al. Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science 232, 881-884 (1986).
77. Maheshwari R, Czarniecki CW, Dutta GP, Puri SK, Dhawan BN, Friedman RM. Recombinant human gamma interferon inhibits simian malaria. Inject. Immun. 53, 628-630 (1986).
78. Mellouk S, Green SJ, Nacy CA, Hoffman SI. IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism J. Immunol. 146, 3971-3976 (1991).
79. + T-cells. J. Exp. Med. 180, 353-358 (1994).
80. Hoffman SL, Crutcher JM, Puff SK et al. Sterile protection of monkeys against malaria after administration of interleukin-12. Nat. Med. 3, 80-83 (1997).
81. Kun JFJ, Lell B, Lehman LG, Luckner D, Kremsner PG. Polymorphism in promoter region of inducible nitric oxide synthase gene and protection against malaria. Lancet 351, 265 (1998). Expression of an iNOS gene mutation is inversely proportional to the severity of clinical P. falciparum. Provides correlative support for NO-mediated protection.
82. Lowin B, Hahne M, Mattmann C, Tschopp J. Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370, 650-652 (1994).
83. Renggli J, Hahne M, Matile H, Betschart B, Tschopp J, Corradin G. Elimination of P. berghei liver stages is independent of Fas (CD95/Apo-I) or perforin-mediated cytotoxicity. Parasite Immunol. 19, 145-148 (1997).
84. Baker MB, Podack ER, Levy RB. Perforin- and Fas-mediated cytotoxic pathways are not required for allogeneic resistance to bone marrow grafts in mice. Biol. Blood Marrow Transplant. 1, 69-73 (1995).
85. Su Z, Stevenson MM. Central role of endogenous gamma interferon in protective immunity against blood-stage Plasmodium chabaudi AS infection. Infect. Immun. 68, 4399-4406 (2000).
86. Tsuji M, Miyahira Y, Nussenzweig RS, Aguet M, Reichel M, Zavala F. Development of antimalaria immunity in mice lacking IFN-gamma receptor. J. Immunol. 154, 5338-5344 (1995).
87. + cytotoxic T-cell clone confers protection against murine malaria. J. Exp. Med. 172, 1353-1357 (1990).
88. Calvo-Calle JM, Hammer J, Sinigaglia F, Clavijo P, Moya-Castro ZR, Nardin EH. Binding of malaria T-cell epitopes to DR and DQ molecules in vitro correlates with immunogenicity in vivo: identification of a universal T-cell epitope in the Plasmodium falciparum circumsporozoite protein. J. Immunol. 159, 1362-1373 (1997).
89. Tsuji M, Mombaerts P, Lefrancois I, Nussenzweig RS, Zavala F, Tonegawa S. Gamma delta T-cells contribute to immunity against the liver stages of mice in alpha beta T-cell-deficient mice. Proc. Natl Acad. Sci. USA 91, 345-349 (1994).
90. McKenna KC, Tsuji M, Sarzotti M, Sacci JB, Witney AA, Azad AF. Gamma delta T-cells are a component of early immunity against preerythrocytic malaria parasites. Infect. Immun. 68, 2224-2230 (2000). Demonstrates that the γδT-cell is a distinct component of early immunity to pre-erythrocytic parasites.
91. + T- lymphocytes is required for protective immunity against Plasmodium berghei. J. Immunol. 156, 3374-3381 (1996).
92. Nardin E, Zavala F, Nussenzweig V, Nussenzweig RS. Pre-erythrocytic malaria vaccine: mechanisms of protective immunity and human vaccine trials. Parassitologia 41, 397-402 (1999).
93. O'Farrelly C, Crispe IN. Prometheus through the looking glass: reflections on the hepatic immune system. Immunol. Today 20, 394-398 (1999).
94. Khan ZM, Vanderberg JP. Eosinophilrich, granulomatous inflammatory response to Plasmodium berghei hepatic schizonts in non-immunized rats is agerelated. Am. J. Trop. Med. Hyg. 45, 190-201 (1991).
95. Faure P, Marussig M, Goosens P, Miltgen F, Mazier D. Characterization of liver lymphomyloid cells in mice infected with Plasmodium yoelii sporozoites. Immunology 82, 645-650 (1994).
96. Faure P, Hukier E, Miltgen F, Renia L, Mazier D. Protective immunity against malaria: Cellular changes in the liver vary according to the method of immunization. Parasite Immunol. 17, 469-477 (1995).
97. Krzych U, Schwenk R, Guebre-Xabier M et al. The role of intrahepatic lymphocytes in mediating protective immunity induced by attenuated Plasmodium berghei sporozoites. Immunol. Rev. 174, 123-134 (2000).
98. + T-cell response to antigenic depots in the liver maintains protection against malaria.
99. Crispe IN, Dao T Klugewitz K, Mehal WZ, Metz DP. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol. Rev. 174, 47-62 (2000).
100. + T-cell protective immunity induced by immunization with Plasmodium berghei CS protein-derived synthetic peptides: evidence that localization of peptide-specific CTLs is crucial for protection against malaria. Immunol. Lett 46, 199-205 (1995).
101. + T-cell clones correlates with their levels of expression of adhesion molecules. J. Exp. Med 175, 895-905 (1991).
102. + cells: New clues to their origin, specificity and function. J. Exp. Med. 182, 633-638 (1995).
103. + T-cells: A new family of T-cells. Immunol. Today 17, 71-76 (1996).
104. + αβ T-cells with intermediary TCR induced in the liver of mice by IL-12. J. Immunol. 154, 4333-4340 (1995).
105. + T-cells in the Plasmodium yoelii model. J. Immunol. 163, 884-892 (1999).
106. + effector function against intercellular infection. J. Exp. Med 184, 131-139 (1996).
107. + αβ T-cells activated by IL-12 as a major inhibition of experimental tumor metastasis. J. Immunol. 156, 3366-3373 (1996).
108. Kaufman SHE. Immunity to intracellular bacteria. Annu. Rev. Immunol. 11, 129-163 (1993).
109. Taylor-Robinson AW, Phillips RS, Severn A, Moncada S, Liew FY. The role of TH1 and TH2 cells in a rodent malaria infection. Science 260, 1931-1934 (1993).
110. + T-lymphocytes producing IL-4 in response to antigens on Plasmodium falciparum erythrocytes: an in vitro correlate of protective immunity induced with attenuated Plasmodium falciparum sporozoites. Cell. Immunol. 180, 143-152 (1997).
111. + TCR alpha beta intermediate cells increase during experimental malaria infection and are able to exhibit inhibitory activity against the parasite liver stage in vitro. J. Immunol. 164, 1463-1469 (2000).
112. Craddock TP, Zumla AM, Ollier WE et al. Predominance of one T-cell antigen receptor BV haplotype in African populations. Immunogenetics 51, 231-237 (2000).
113. + T-cell-driven IFN-γ responses to conserved epitopes of LSA-1 common in residents of a malaria-endemic region is consistent with a role for this T-cell population in immunity to liver-stage P. falciparum in humans.
114. Bucci K, Kastens W, Hollingdale MR et al. Influence of age and HLA type on IFN-γ responses to a naturally occurring polymorphic epitope of Plasmodium falciparum liver stage antigen-1. Clin. Exp. Immunol. 122, 94-100 (2000). Supports the notions of MHC class I allele selection by malaria and of age-related cumulative exposure increasing the frequency of IFN-γ responses to LSAs.
115. John CC, Sumba PO, Ouma JH, Nahlen BL, King CL, Kazura JW. Cytokine responses to Plasmodium falciparum liverstage antigen 1 vary in rainy and dry seasons in highland Kenya. Infect. Immun. 68, 5198-5204 (2000).
116. Luty AJ, Lell B, Schmidt-Ott R et al. Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J. Infect. Dis. 179, 980-988 (1999).
117. May J, Lell B, Luty AJ, Meyer CG, Kremsner PG. HLA-DQB1*0501-restricted Th1 type immune responses to Plasmodium falciparum liver stage antigen 1 protect against malaria anemia and reinfections. J. Infect. Dis. 183, 168-172 (2001).
118. Kurtis JD, Lanar DE, Opollo M, Duffy PE. Interleukin-10 responses to liver-stage antigen 1 predict human resistance to Plasmodium falciparum. Infect. Immun. 67, 3424-3429 (1999).
119. Luty AJ, Lell B, Schmidt-Ott R et al. Parasite antigen-specific interleukin-10 and antibody responses predict accelerated parasite clearance in Plasmodium falciparum malaria. Eur. Cytokine Netw. 9, 639-646 (1998).
120. Domarle O, Migot-Nabias F, Mvoukani JL et al. Factors influencing resistance to reinfection with Plasmodium falciparum. Am. J. Trop. Med. Hyg. 61, 926-931 (1999).
121. Migot-Nabias F, Deloron P, Ringwald P et al. Immune response to Plasmodium falciparum liver stage antigen-1: geographical variations within Central Africa and their relationship with protection from clinical malaria. Trans. R. Soc. Trop. Med. Hyg. 94, 557-562 (2000).
122. + T-cell epitope of Plasmodium falciparum. Immunity 10, 651-660 (1999).
123. Rousset, F, Garcia E, Defrance T et al. Interleukin-10 is a potent growth and differentiation factor for activated human B-lymphocytes. Proc. Natl Acad. Sci. USA 89, 1890-1893 (1992).
124. + T-lymphocyte migration. J. Immunol. 151, 4545-4551 (1993).
125. Aidoo M, Lalvani A, Gilbert SC et al. Cytotoxic T-lymphocyte epitopes for HLA-B53 and other HLA types in the malaria vaccine candidate liver-stage antigen 3. Infect. Immun. 68, 227-232 (2000). Emphasizes that an effective pre-erythrocytic vaccine against P. falciparum is likely to require inclusion of components from several exoerythrocytic antigens.
126. Pasquetto V, Fidock DA, Gras H et al. Plasmodium falciparum sporozoite invasion is inhibited by naturally acquired or experimentally induced polyclonal antibodies to the STARP antigen. Eur. J. Immunol. 27, 2502-2513 (1997).
127. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, Druilhe P. Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect. Immun. 68, 2617-2620 (2000).
128. Theisen M, Soe S, Oeuvray C et al. The glutamate-rich protein (GLURP) of Plasmodium falciparum is a target for antibody-dependent monocyte-mediated inhibition of parasite growth in vitro. Infect. Immun. 66, 11-17 (1998).
129. Syin C, Goldman ND. Cloning of a Plasmodium falciparum gene related to the human 60-kDa heat shock protein. Mol. Biochem. Parasitol. 79, 13-19 (1996).
130. Sheikh N, Al-Shamisi M, Morrow WJW. Delivery systems for molecular vaccination. Curr. Opin. Mol. Ther. 2, 37-54 (2000).
131. Singh M, O'Hagan D. Advances in vaccine adjuvants. Nat. Biotechnol. 17, 1075-1081 (1999).
132. Stoute JA, Slaoui M, Heppner DG et al. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N. Engl. J. Med. 336, 86-91 (1997). RTS,S vaccine protected six out of seven volunteers against experimental challenge with P. falciparum sporozoites, thus indicating progression to field evaluation (see ref. [133]).
133. Bojang KA, Milligan PJ, Pinder M et al. Efficacy of RTS,S/AS02 malaria vaccine against Plasmodium falciparum infection in semi-immune adult men in The Gambia: a randomised trial. Lancet 358, 1927-1934 (2001). Describes clinical trial of the first pre-erythrocytic vaccine to show significant protection (34% over 15 weeks) against natural P. falciparum.
134. Gonzales-Aseguinolaza G, de Oliveira C, Tomaska M et al. α-galactosylceramide-activated Vα14 natural killer T-cells mediate protection against murine malaria. Proc. Natl Acad. Sci. USA 97, 8461-8466 (2000). See ref. [135].
135. Gonzales-Aseguinolaza G, Van Kaer L, Bergmann CC et al. Natural killer T-cell ligand α-galactosylceramide enhances protective immunity induced by malaria vaccines. J. Exp. Med 195, 617-624 (2002). Shows the potential of α-GalCer as an adjuvant capable of enhancing cell-mediated immunity, through the activation of NK-T-cells.
136. Krieg AM, Yi AK, Matson S et al. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 374, 546-549 (1995).
137. Weiner GJ. CpG DNA in cancer immunotherapy. Curr. Top. Microbiol. Immunol. 247, 157-170 (2000).
138. Askenase PW. Gee whiz: CpG DNA allergy therapy! J. Allergy Clin. Immunol. 106, 37-40 (2000).
139. Deml L, Schirmbeck R, Reimann J, Wolf H, Wagner R. Immunostimulatory CpG motifs trigger a T-helper-1 immune response to human immunodeficiency virus type-1 (HIV-1) gp 160 envelope proteins. Clin. Chem. Lab. Med 37, 199-204 (1999).
140. Stacey KJ, Blackwell JM. Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect. Immun. 67, 3719-3726 (1999).
141. Klinman DM, Ishii KJ, Verthelyi D. CpG DNA augments the immunogenicity of plasmid DNA vaccines. Curr. Top. Microbiol. Immunol. 247, 131-142 (2000).
142. Klinman DM, Yamshchikov G, Ishigatsubo Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 1158, 3635-3639 (1997).
143. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: immunology, application and optimization. Annu. Rev. Immunol. 18, 927-974 (2000).
144. Jones TR, Obaldia N III, Gramzinski RA et al. Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. Vaccine 17, 3065-3071 (1999).
145. Warren TL, Weiner GJ. Uses of granulocyte-macrophage colony-stimulating factor in vaccine development. Curr. Opin. Hematol. 7, 168-173 (2000).
146. Kamath AT, Hanke T, Briscoe H, Britton WJ. Co-immunization with DNA vaccines expressing granulocyte-macrophage colony-stimulating factor and mycobacterial secreted proteins enhances T-cell immunity but not protective efficacy against Mycobacterium tuberculosis. Immunology 96, 511-516 (1999).
147. Sin JI, Kim JJ, Ugen KE, Ciccarelli RB, Higgins TJ, Weiner DB. Enhancement of protective humoral (Th2) and cell-mediated (Th1) immune responses against herpes simplex virus-2 through co-delivery of granulocyte-macrophage colony-stimulating factor expression cassettes. Eur. J. Immunol. 28, 3530-3540 (1998).
148. Ishii KJ, Weiss WR, Klinman DM. Prevention of neonatal tolerance by a plasmid encoding granulocyte-macrophage colony stimulating factor. Vaccine 18, 703-710 (1999).
149. Owhashi M, Uemura H, Kanbara H, Nawa Y. Granulocyte-macrophage colony-stimulating factor production by T-lymphocytes in Plasmodium berghei-infected mice. Southeast Asian J. Trop. Med. Public Health 28, 757-763 (1997).
150. Weiss WR, Ishii KJ, Hedstrom RC et al. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol. 161, 2325-2332 (1998).
151. Sedegah M, Weiss W, Sacci JB et al. Improving protective immunity induced by DNA-based immunization: priming with antigen and GM-CSF-encoding plasmid DNA and boosting with antigen-expressing recombinant poxvirus. J. Immunol. 164, 5905-5912 (2000).
152. Parker SE, Monteith D, Horton H et al. Safety of a GM-CSF adjuvant-plasmid DNA malaria vaccine. Gene Ther. 8, 1011-1023 (2001).
153. Reitermann A, Metzger J, Wiesmuller KH, Jung G, Bessler WG. Lipopeptide derivatives of bacterial lipoprotein constitute potent immune adjuvants combined with or covalently coupled to antigen or hapten. Biol. Chem. Hoppe Seyler 370, 343-352 (1989).
154. Bessler WG, Jung G. Synthetic lipopeptides as novel adjuvants. Res. Immunol. 143, 548-553 (1992).
155. Schild H, Deres K, Wiesmuller KH, Jung G, Rammensee HG. Efficiency of peptides and lipopeptides for in vivo priming of virus-specific cytotoxic T-cells. Eur. J. Immunol. 21, 2649-2654 (1991).
156. Taylor-Robinson AW, Morrow WJW. Tomatine as an adjuvant in malaria vaccine development. Drugs Fut. 27, 391-402 (2002).
157. + T-cell responses against exoerythrocytic malaria parasites.
158. Ockenhouse CF, Sun PF, Lanar DE et al. Phase I/IIa safety, immunogenicity and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J. Infect. Dis. 177, 1664-1673 (1998).
159. Aidoo M, Lalvani A, Allsopp CE et al. Identification of conserved antigenic components for a cytotoxic T-lymphocyte-inducing vaccine against malaria. Lancet 345, 1003-1007 (1995).
160. Heal KG, Hill HR, Stockley PG, Hollingdale MR, Taylor-Robinson AW. Expression and immunogenicity of a liver stage malaria epitope presented as a foreign peptide on the surface of RNA-free MS2 bacteriophage capsids. Vaccine 18, 251-258 (1999).
161. Deprez B, Sauzet JP, Boutillon C et al. Comparative efficiency of simple lipopeptide constructs for in vivo induction of virus-specific CTL. Vaccine 14, 375-382 (1996).
162. Ben Mohamed L, Gras-Masse H, Tartar A et al. Lipopeptide immunization without adjuvant induces potent and long-lasting B, T-helper and cytotoxic T-lymphocyte responses against a malaria liver stage antigen in mice and chimpanzees. Eur. J. Immunol. 27, 1242-1253 (1997).
163. Perlaza BL, Arevalo-Herrera M, Brahimi K et al. Immunogenicity of four Plasmodium falciparum preerythrocytic antigens in Aotus lemurinus monkeys. Infect. Immun. 66, 3423-3428 (1998).
164. Ben Mohamad L, Thomas A, Bossus M et al. High immunogenicity in chimpanzees of peptides and lipopeptides derived from four new Plasmodium falciparum pre-erythrocytic molecules. Vaccine 18, 2843-2855 (2000).
165. Schild H, Norda M, Deres K et al. Fine specificity of cytotoxic T-lymphocytes primed in vivo either with virus or synthetic lipopeptide vaccine or primed in vitro with peptide. J. Exp. Med. 174, 1665-1668 (1991).
166. Theisen M, Vuust J, Gottschau A, Jepsen S, Hogh B. Antigenicity and immunogenicity of recombinant glutamate-rich protein of Plasmodium falciparum expressed in Escherichia coli. Clin. Diagn. Lab. Immunol. 2, 30-34 (1995).
167. + T-cell-mediated protective immunity against malaria. Proc. Natl Acad. Sci. USA 90, 5214-5218 (1993).
168. Bruna-Romero O, Gonzalez-Aseguinolaza G, Hafalla JC, Tsuji M, Nussenzweig RS. Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen. Proc. Natl Acad. Sci. USA 98, 11491-11496 (2001). See ref. [169].
169. + T-cells. Virology 280, 155-159 (2001). Provides a proof-of-concept for using recombinant viruses expressing plasmodial antigen for prime-boost immunization against pre-erythrocytic malaria.
170. Sedegah M, Jones TR, Kaur M et al. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl Acad. Sci. USA 95, 7648-7653 (1998). See ref. [171].
171. Hanke T, Blanchard TJ, Schneider J et al. Enhancement of MHC class I restricted peptide-specific T-cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445 (1998).
172. + T-cell immunogenicity and protective efficacy in the influenza and malaria models. Vaccine 18, 623-632 (1999).
173. Yoshida S, Kashiwamura SI, Hosoya Yet al. Direct immunization of malaria DNA vaccine into the liver by gene gun protects against lethal challenge of Plasmodium berghei sporozoite. Biochem. Biophys. Res. Comm. 271, 107-115 (2000).
174. Layton GT, Harris SJ, Myhan J et al. Induction of single and dual cytotoxic T-lymphocyte responses to viral proteins in mice using recombinant hybrid Ty-virus-like particles. Immunology 87, 171-178 (1996).
175. Gilbert SC, Schneider J, Plebanski M et al. Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara: comparisons and combinations. Biol Chem. 380, 299-303 (1999).
176. Plebanski M, Gilbert SC, Schneider J et al. Protection from Plasmodium berghei infection by priming and boosting T-cells to a single Class I-restricted epitope with recombinant carriers suitable for human use. Eur. J. Immunol. 28, 4345-4355 (1998). See ref. [177].
177. Gilbert SC, Plebanski M, Harris SJ et al. A protein particle vaccine containing multiple malaria epitopes. Nat. Biotechnol. 12, 1280-1284 (1997). Provides a proof-of-concept for using Ty particles expressing plasmodial antigen, then recombinant virus, for prime-boost immunization against pre-erythrocytic malaria.
178. + T-cell epitope of the CS protein of P. yoelii enhanced memory response by boosting with recombinant vaccinia virus. Vaccine 18, 1863-1869 (2000).
179. Gilbert SC, Schneider J, Hannan CM et al. Enhanced CD8 T-cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20, 1039-1045 (2002).